business
Merck’s Enlicitide Decanoate, an Investigational Oral PCSK9 Inhibitor, Significantly Reduced LDL-C in Phase 3 CORALreef Lipids Trial - Merck.com
Merck Announces Groundbreaking Results in Phase 3 Clinical Trial for New Lipid Treatment In a significant development in the field of cardiovascular disease treatment, Merck (NYSE: MRK), also known as MSD outside of the United States and Canada, has announced the first presentation of results from its pivotal Phase 3